The manufacturing standard
A peptide is built one amino acid at a time.
Then purified, tested, filled under sterile air, tested again, and tracked to your door. Here is the whole journey — six stages, and what has to pass at each one.
Written by Eric W. Anderson, MD · Last updated
- 1
Synthesis
chain built
- 2
Purification
impurities cut out
- 3
API release
raw material tested
- 4
Sterile fill
into the vial
- 5
Batch release
vial tested
- 6
Delivery
cold chain to you
Synthesis
The chain is assembled one residue at a time
Most therapeutic peptides are built by solid-phase peptide synthesis. The chain is anchored to a resin bead and grown one amino acid per cycle. A 30-residue peptide means roughly 30 rounds of the same four steps — and every round is a chance to introduce a defect.
On the resin
Each cycle
A missed coupling leaves a peptide missing a residue. Capping ends those chains early, so they can be separated out later instead of riding along.
Purification
The impurities are physically cut away
Crude peptide off the resin is nowhere near clean. It runs through preparative chromatography, which separates the target from everything close to it. Only the material under the collection window is kept. Published pharmaceutical processes reach 99.5%+, with every individual impurity under 0.1%.
Those small side peaks are the whole point. A cheap process keeps them. A good one throws away yield to remove them.
≥99%
Main-peak purity target for pharmaceutical-grade peptide API
<0.1%
Ceiling for any single impurity in a well-run process
2×
Orthogonal methods required — one test is never proof of identity
API release
Nine tests before the raw material is allowed in
A Certificate of Analysis is not one number. At pharmaceutical grade it is a panel — each test catching a different way the material can be wrong. Purity alone tells you almost nothing, because it's a UV area percentage that can't see water, salt, or the wrong-handed version of your molecule.
Identity — mass
Mass spectrometry confirms the molecule weighs what it should, within ~1 unit.
USP <736>Identity — sequence
Peptide mapping confirms the residues are in the right order, not just present.
USP <1055>Purity & assay
RP-HPLC area percent measured against a qualified reference standard.
USP <621>Related substances
Deletion, truncation and insertion sequences quantified individually.
USP <1503>Chiral purity
D-isomers are invisible to standard HPLC. They need their own method.
Marfey's / LC-MSWater content
Karl Fischer. Peptides are hygroscopic — water is real mass in the vial.
USP <921>Residual solvents
Gas chromatography for the solvents used during synthesis and purification.
USP <467> · ICH Q3CElemental impurities
ICP-MS for metals carried in from reagents or equipment.
USP <232> · ICH Q3DEndotoxin & bioburden
Bacterial residue and microbial load, before the material reaches a fill room.
USP <85> · <61>The misreading that costs people money
"99% pure" — what it measures
peptide-related impurities only
Net peptide content — what's actually in the vial
often under 90%
Sterile fill
The vial is open for seconds. That's the whole risk.
Sterility can't be added afterward — it has to be protected at the one moment the container is open. So the air above the fill point is filtered and flows in one direction, at a controlled speed, into progressively cleaner zones. The room is part of the specification.
Grade A allows zero detectable microbial growth. Not "low" — zero. Air, surfaces and operator gloves are monitored while the line is running.
0.22 µm
Sterilizing filter — smaller than the bacteria it removes
250°C
Dry-heat tunnel that depyrogenates the glass before filling
Zero
Permitted microbial growth in the Grade A critical zone
100%
Of filled vials inspected individually for particles and defects
Batch release
The finished vial has to pass on its own
Testing the powder isn't testing the product. Once filled and sealed, the batch is tested again — and the sterility test alone takes fourteen days of incubation before anyone can call it. That waiting period is the difference between a real release process and a shipping label.
USP <85>
Day 0
Endotoxin
filled & sealed
USP <788>
Particulates · pH
appearance
USP <1207>
Seal integrity
assay
USP <71>
Sterility
14-day incubation
Released
batch record signed
Anything outside specification is rejected — not downgraded, not relabeled, not sold at a discount.
Delivery
Cold the whole way, and traceable at the end of it
A perfect vial can still be ruined in transit. Temperature is logged from the moment it leaves the facility, and any excursion outside range has to be assessed against stability data before the product can be released for sale. The lot number on your vial is what ties all of it back together.
Logged continuously by calibrated data logger. An excursion isn't automatically a rejection — but it does trigger a documented assessment before anything ships.
One number links the whole chain
If a company can't hand you the paperwork for your specific lot, none of the steps above can be verified — by you or by anyone.
Related reading
The chain of custody behind a finished vial
Six checkpoints and the record attached to each stage.
What a certificate of analysis establishes
How to read the document attached to a specific lot — and its limits.
Purity, sterility, and endotoxin
Three different properties measured by three different tests.